|
gptkbp:instanceOf
|
Synthetic polymer
Colloid volume expander
|
|
gptkbp:administeredBy
|
Intravenous infusion
|
|
gptkbp:alternativeName
|
gptkb:HES
gptkb:Hydroxyethylated_starch
|
|
gptkbp:ATCCode
|
gptkb:B05AA07
|
|
gptkbp:CASNumber
|
gptkb:9005-27-0
|
|
gptkbp:contraindication
|
Sepsis
Critical illness
Renal failure
|
|
gptkbp:derivedFrom
|
Amylopectin
|
|
gptkbp:discoveredIn
|
20th century
|
|
gptkbp:excretion
|
gptkb:Kidneys
|
|
gptkbp:halfLife
|
Varies by molecular weight and substitution
|
|
gptkbp:hasMolecularFormula
|
(C2H4O)n
|
|
gptkbp:hasOsmolality
|
Iso-oncotic or hyperoncotic
|
|
gptkbp:hasPhysicalForm
|
gptkb:parade
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Hydroxyethyl starch
|
|
gptkbp:isSolubleIn
|
gptkb:water
|
|
gptkbp:metabolism
|
gptkb:Amylase
|
|
gptkbp:molecularWeight
|
Varies (typically 130-450 kDa)
|
|
gptkbp:regulates
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:riskFactor
|
Increased mortality in critically ill patients
Risk of kidney injury
|
|
gptkbp:sideEffect
|
Coagulopathy
Anaphylactoid reactions
Renal impairment
|
|
gptkbp:usedFor
|
Plasma volume expansion
Treatment of hypovolemia
|
|
gptkbp:bfsParent
|
gptkb:HES
|
|
gptkbp:bfsLayer
|
6
|